ISPOR Europe 2024 Home
  • About
    • News Center
  • Award Winners
  • Program
    • Program
    • Student Program
    • Learning Formats
    • Plenary Sessions
    • Posters
    • Program Committee
    • Digital Conference Pass
  • Exhibits & Sponsorship
    • Sponsor List
    • Media Partners
    • Exhibitor Directory
  • Photo Gallery
large-circle

ISPOR Europe 2024

17 - 20 November

  • Home
  • Events
  • Past Conferences
  • ISPOR Europe 2024
  • Program
  • Plenary Sessions
  • Session

  • Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data From the 8.4-Year Follow-up of APHINITY

    Nov 19, 2024, 10:30 AM
  • «
  • 1641
  • 1642
  • 1643
  • 1644
  • 1645
  • 1646
  • 1647 (current)
  • 1648
  • 1649
  • 1650
  • »
Quick Links
  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal
  • AI Policy
  • Antitrust Compliance
  • Code of Ethics
  • Cookie Policy
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Terms and Conditions

Subscribe

Join ISPOR

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group